EPHX2 and COVID-19: As EpFAs are rapidly metabolized by sEH, administration of sEH inhibitors can stabilize and increase EpFA levels, prevent lung inflammation, and improve lung function, making them a potential therapeutic strategy in the fight against COVID‐19.